SecBot SecBot

SNY

Sanofi
Nasdaq· Pharmaceutical Preparations· Inc. I0· CIK 0001121404 Biotech & Drug Discovery
$48.37 −0.09 (−0.19%)
Nov 13 4:00 PM ET · prev $48.46
Market cap
$118.2B
Large cap
Median target
$55.80
+15% · range $45.00–63.00
1 year
−6.6%
from $51.78 · Nov 17
30 days
+22.2%
from $39.57
52-week range
$39.12–51.78
−7% from high · low Oct 13
Avg volume 20D
4.51M
Oct 30 spike 15.10M
Short interest
12.29M
≈0.5% of shares · +5.8%
Days to cover
2.9
at average volume
New fund stakes
1
Q3 2026 13F · 1 exit
Filing reports
15
analyzed by SecBot
SecBot read BULLISH 8 reports · 90 days
Balance 0 bearish · 2 bullish · 1 mixed · 5 neutral oldest → newest, height = score
Avg score ·High conf. 7/8

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InstitutionsBULLISH

    Q3 2026: 33 added (1 new), 21 trimmed or exited.

  • Short sellersSTEADY

    Short interest +5.8% to 12.29M shares. 2.9 days to cover, ≈0.5% of shares.

  • TrendUPTREND

    13% above its 50-day average.

Who's buying

13F· Q3 2026
1
new positions
1
exit
FundMoveSharesValue
DODGE & COXTRIM15,668,529$646.0M
MORGAN STANLEYADD14,900,060$614.3M
FEDERATED HERMES, INC.ADD5,455,928$224.9M
Qube Research & Technologies LtdDOUBLED2,164,755$89.3M
BARCLAYS PLCTRIM1,573,455$64.9M
BANK OF MONTREAL /CAN/DOUBLED1,276,670$52.6M
Grantham, Mayo, Van Otterloo & Co. LLCADD412,226$17.0M
Cullen Capital Management, LLCTRIM393,743$16.2M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Jan 2026
12-month targets · 9 analysts

Price is inside the target range. Median implies +15%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Jan 16, 2026UBS
DOWNGRADE
DOWNGRADENeutral
Jan 6, 2026Barclays
DOWNGRADE
DOWNGRADEEqual-Weight
Dec 9, 2025Guggenheim
DOWNGRADE
DOWNGRADENeutral
Dec 8, 2025JP Morgan
DOWNGRADE
DOWNGRADENeutral
Sep 8, 2025Morgan Stanley
UPGRADE
UPGRADEOverweight
Sep 2, 2025Deutsche Bank
UPGRADE
UPGRADEBuy

Short side

FINRA· Oct 30, 2026
12,291,525
shares short
+5.8%
vs prior settlement
2.9
days to cover
≈0.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 4, 2026 SEC
Three asset managers increased Sanofi holdings by $5.7M in Q3 2026, led by Pzena more than quadrupling its stake…
INST-CLUSTER · Impact 2/10
Nov 1, 2026 Clinical trial readout
T-90d Trial Readout: Investigational hMPV/RSV vaccine (Phase 2)
Trial: Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsula
Oct 30, 2026 SEC
Sanofi reported Q3 2026 net sales of €14,444M (+14.3% CER) and business EPS of €3.55 (+19.6% CER), both showing…
6-K · Impact 6/10
Oct 26, 2026 SEC
Amundi filed an amended Schedule 13G disclosing a 5.70% passive stake in Sanofi as of September 30, 2026, up from…
SC 13G/A · Impact 2/10
Oct 14, 2026 Event
Opening remarks by Executive Vice-President Teresa Ribera on the Commission decision to accept commitments by Sanofi
European Commission Speech Brussels, 14 Oct 2026 Good morning, everybody. I'm happy to see you here
Sep 30, 2026 Inst.
DODGE & COX · TRIM
15,668,529 shares ($646.0M)
Sep 30, 2026 Inst.
MORGAN STANLEY · ADD
14,900,060 shares ($614.3M)
Sep 18, 2026 Event
RIFADIN IV
Unavailable: Discontinuation of the manufacture of the drug (Discontinuation of the manufacture of t

SecBot reports

15 filings · 5 bullish · 1 bearish · 2 mixed · 7 neutral
All SNY filing & press-release reports (15)